Short Interest in Rein Therapeutics Inc. (NASDAQ:RNTX) Increases By 76.0%

Rein Therapeutics Inc. (NASDAQ:RNTX) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 351,493 shares, a growth of 76.0% from the December 31st total of 199,688 shares. Based on an average trading volume of 131,187 shares, the short-interest ratio is currently 2.7 days. Currently, 1.4% of the company’s shares are sold short. Currently, 1.4% of the company’s shares are sold short. Based on an average trading volume of 131,187 shares, the short-interest ratio is currently 2.7 days.

Insiders Place Their Bets

In other news, major shareholder Voss Capital, Lp purchased 104,183 shares of the stock in a transaction on Friday, November 14th. The stock was purchased at an average price of $1.22 per share, for a total transaction of $127,103.26. Following the acquisition, the insider owned 926,441 shares in the company, valued at $1,130,258.02. This trade represents a 12.67% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Blair William & Co. IL bought a new stake in shares of Rein Therapeutics during the second quarter worth about $33,000. Chicago Partners Investment Group LLC bought a new stake in Rein Therapeutics during the 2nd quarter worth approximately $64,000. Exencial Wealth Advisors LLC purchased a new stake in shares of Rein Therapeutics in the second quarter worth approximately $43,000. University of Texas Texas AM Investment Management Co. bought a new position in shares of Rein Therapeutics in the second quarter valued at approximately $716,000. Finally, Sigma Planning Corp bought a new stake in Rein Therapeutics during the second quarter worth $387,000. 90.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

RNTX has been the subject of a number of analyst reports. Citigroup downgraded shares of Rein Therapeutics to a “hold” rating in a research note on Wednesday, January 21st. Wall Street Zen lowered Rein Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Thursday, January 22nd. Brookline Capital Management cut Rein Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 21st. Finally, Loop Capital set a $6.00 price target on Rein Therapeutics in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Price Performance

Shares of RNTX opened at $1.30 on Friday. Rein Therapeutics has a one year low of $1.02 and a one year high of $2.96. The company has a market cap of $34.17 million, a PE ratio of -0.49 and a beta of 1.31. The stock has a 50-day moving average of $1.34 and a 200-day moving average of $1.31.

Rein Therapeutics (NASDAQ:RNTX) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.03. Analysts expect that Rein Therapeutics will post -1.56 EPS for the current fiscal year.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.